PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.19%
Positive revenue growth while 3088.T is negative. John Neff might see a notable competitive edge here.
1.77%
Positive gross profit growth while 3088.T is negative. John Neff would see a clear operational edge over the competitor.
-21.19%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-22.23%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
9.10%
Positive net income growth while 3088.T is negative. John Neff might see a big relative performance advantage.
9.10%
Positive EPS growth while 3088.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
9.10%
Positive diluted EPS growth while 3088.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Share reduction while 3088.T is at 0.02%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.03%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
15.38%
Dividend growth of 15.38% while 3088.T is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
145.37%
10Y revenue/share CAGR 1.25-1.5x 3088.T's 118.56%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
35.19%
5Y revenue/share CAGR under 50% of 3088.T's 86.06%. Michael Burry would suspect a significant competitive gap or product weakness.
31.75%
3Y revenue/share CAGR above 1.5x 3088.T's 20.99%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
144.02%
Net income/share CAGR at 50-75% of 3088.T's 245.92%. Martin Whitman might question if the firm’s product or cost base lags behind.
19.91%
Below 50% of 3088.T's 91.18%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
28.78%
Below 50% of 3088.T's 138.67%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
295.46%
10Y equity/share CAGR 1.25-1.5x 3088.T's 240.15%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
76.61%
5Y equity/share CAGR at 50-75% of 3088.T's 134.66%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
35.05%
3Y equity/share CAGR above 1.5x 3088.T's 15.89%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
361.54%
Similar 10Y dividend/share CAGR to 3088.T's 360.00%. Walter Schloss expects both to share consistent earnings expansions and payout practices.
150.00%
5Y dividend/share CAGR above 1.5x 3088.T's 97.14%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
87.50%
3Y dividend/share CAGR similar to 3088.T's 97.14%. Walter Schloss finds parallel short-term dividend strategies for both companies.
1721.43%
AR growth well above 3088.T's 38.39%. Michael Burry fears inflated revenue or higher default risk in the near future.
4.84%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
10.68%
Positive asset growth while 3088.T is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
3.47%
1.25-1.5x 3088.T's 2.55%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
75.11%
We have some new debt while 3088.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
8.24%
We expand SG&A while 3088.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.